|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
98,530,000 |
Market
Cap: |
18.88(M) |
Last
Volume: |
78,874 |
Avg
Vol: |
78,656 |
52
Week Range: |
$0.1916 - $0.1916 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
31,758 |
51,758 |
77,758 |
93,627 |
Total Buy Value |
$102,237 |
$190,037 |
$294,295 |
$352,590 |
Total People Bought |
4 |
4 |
4 |
4 |
Total Buy Transactions |
4 |
5 |
8 |
11 |
Total Shares Sold |
0 |
7,084 |
41,479 |
98,636 |
Total Sell Value |
$0 |
$36,199 |
$179,159 |
$193,613 |
Total People Sold |
0 |
1 |
5 |
5 |
Total Sell Transactions |
0 |
1 |
8 |
13 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mann Paul Elliot |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
38,590 |
|
- |
|
Wider Todd |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
63,590 |
|
- |
|
Charles Faith L. |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
Alland Leila |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
Rouhandeh Steven H |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
533,590 |
|
- |
|
Alvino Mark |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
82,181 |
|
- |
|
Wuchterl Donald A. |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
Silverstein Christine Berni |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
118,590 |
|
- |
|
Rouhandeh Steven H |
Director |
|
2021-05-03 |
4 |
AS |
$2.01 |
$160,888 |
I/I |
(80,000) |
11,079,292 |
|
-36% |
|
Amoroso Michael |
Chief Executive Officer |
|
2021-03-31 |
4 |
AS |
$1.87 |
$84,919 |
D/D |
(45,409) |
650,046 |
|
-33% |
|
Amoroso Michael |
Chief Executive Officer |
|
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
695,455 |
|
- |
|
Rouhandeh Steven H |
Director |
|
2021-03-18 |
4 |
AS |
$2.23 |
$178,624 |
I/I |
(80,000) |
11,159,292 |
|
-40% |
|
Carr Edward |
Chief Accounting Officer |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
246,736 |
|
- |
|
Amoroso Michael |
Chief Operating Officer |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
445,455 |
|
- |
|
Mann Paul Elliot |
Director |
|
2021-02-19 |
4 |
S |
$2.38 |
$108,502 |
D/D |
(45,566) |
0 |
|
35% |
|
Mann Paul Elliot |
Director |
|
2021-02-19 |
4 |
OE |
$1.28 |
$58,324 |
D/D |
45,566 |
45,566 |
|
- |
|
Wider Todd |
Director |
|
2021-02-19 |
4 |
S |
$2.39 |
$601,057 |
D/D |
(251,625) |
25,000 |
|
35% |
|
Wider Todd |
Director |
|
2021-02-18 |
4 |
S |
$2.43 |
$3,273 |
D/D |
(1,345) |
276,625 |
|
33% |
|
Wider Todd |
Director |
|
2021-02-18 |
4 |
OE |
$1.28 |
$1,722 |
D/D |
1,345 |
277,970 |
|
- |
|
Wider Todd |
Director |
|
2021-02-17 |
4 |
S |
$2.34 |
$749,792 |
D/D |
(320,000) |
276,625 |
|
36% |
|
Wider Todd |
Director |
|
2021-02-17 |
4 |
OE |
$1.28 |
$409,600 |
D/D |
320,000 |
596,625 |
|
- |
|
Mann Paul Elliot |
Director |
|
2021-02-17 |
4 |
S |
$2.34 |
$310,168 |
D/D |
(132,664) |
0 |
|
36% |
|
Rouhandeh Steven H |
Director |
|
2021-02-16 |
4 |
AS |
$2.97 |
$356,808 |
I/I |
(120,000) |
11,239,292 |
|
-38% |
|
Rouhandeh Steven H |
Director |
|
2021-02-08 |
4 |
AS |
$3.01 |
$722,832 |
I/I |
(240,000) |
11,359,292 |
|
-50% |
|
Rouhandeh Steven H |
Director |
|
2021-01-19 |
4 |
AS |
$2.08 |
$431,218 |
I/I |
(207,117) |
11,599,292 |
|
-23% |
|
156 Records found
|
|
Page 4 of 7 |
|
|